J. Pierga

B. Chauffert, M. Ychou, M. Ducreux, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.

B. Chauffert, T. Conroy, M. Ducreux, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.

D. Doval, J. Pierga, E. Alba, 2014, The Lancet. Oncology.

Preliminary experience of whole-brain radiation therapy (WBRT) in breast cancer patients with brain metastases previously treated with bevacizumab-based chemotherapy

M. Bollet, J. Pierga, A. Fourquet, 2011, Journal of Neuro-Oncology.

Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients.

Cyrus Chargari, M. Bollet, J. Pierga, 2011, International journal of radiation oncology, biology, physics.

Myocardial perfusion damage after mediastinal irradiation for Hodgkin's disease: a thallium-201 single photon emission tomography study

C. Maunoury, J. Pierga, J. Cosset, 2004, European Journal of Nuclear Medicine.

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

B. Xu, X. Pivot, J. Pierga, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study

J. Pierga, I. Smith, C. Thomssen, 2012, Oncology.

Efficacy and tolerance of everolimus in 123 consecutive advanced ER positive, HER2 negative breast cancer patients. A two center retrospective study.

H. Bonnefoi, J. Pierga, V. Diéras, 2015, Breast.

Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients

Cyrus Chargari, J. Pierga, V. Diéras, 2009, Journal of Neuro-Oncology.

LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR).

M. Campone, G. Romieu, J. Pierga, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.

D. Miles, J. Pierga, K. Pritchard, 2012, European journal of cancer.

Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinoma.

A. Vincent-Salomon, J. Klijanienko, F. Bidard, 2009, European journal of cancer.

Prognostic Value of Cytokeratin 19 Fragment (CYFRA 21–1) and Cytokeratin-Positive Cells in Bone Marrow Samples of Breast Cancer Patients

J. Thiery, A. Vincent-Salomon, J. Pierga, 2004 .

Prognostic value of cytokeratin 19 fragment (CYFRA 21-1) and cytokeratin-positive cells in bone marrow samples of breast cancer patients.

J. Thiery, A. Vincent-Salomon, J. Pierga, 2004, The International journal of biological markers.

PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer

F. Bertucci, T. Petit, J. Pierga, 2020, Frontiers in Oncology.

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab

F. Bertucci, F. André, J. Lemonnier, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study

F. Bertucci, D. Birnbaum, P. Finetti, 2016, Oncotarget.

Circulating Tumor Cells in Early Breast Cancer

F. Bidard, J. Pierga, A. Latouche, 2019, JNCI cancer spectrum.

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

A. Tutt, M. Piccart, C. Hudis, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

A. Tutt, M. Piccart, C. Hudis, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

A. Tutt, M. Piccart, C. Hudis, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies

A. Vincent-Salomon, M. Bollet, J. Pierga, 2008, British Journal of Cancer.

Are ipsilateral breast tumour invasive recurrences in young (⩽40 years) women more aggressive than their primary tumours?

A. Vincent-Salomon, M. Bollet, J. Pierga, 2007, British Journal of Cancer.

Predictive Biomarkers and Personalized Medicine Establishment and Validation of Circulating Tumor Cell – Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients

G. Hortobagyi, A. Giordano, B. Egleston, 2013 .

M. Campone, F. Bidard, J. Pierga, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer

Leonie L. Zeune, F. Bidard, J. Pierga, 2020, Breast Cancer Research.

Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial.

V. Servois, B. Asselain, F. Bidard, 2015, Cancer letters.

Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer.

M. Campone, F. Bidard, J. Pierga, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.

F. Bidard, J. Pierga, O. Bouché, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Implementing circulating tumor cells in routine practice of breast cancer management: overview of the interventional trials

T. Fehm, M. Piccart, M. Ignatiadis, 2013 .

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

T. Fehm, C. Caldas, J. Reis-Filho, 2014, The Lancet. Oncology.

Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial

F. Bidard, J. Pierga, A. Gonçalves, 2021, Cancers.

Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.

M. Espié, F. Bidard, J. Pierga, 2020, JAMA oncology.

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

M. Espié, M. Bollet, F. Bidard, 2019, Breast Cancer Research.

Clinical utility of circulating tumor cells in metastatic breast cancer.

F. Bidard, J. Pierga, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumor cells in breast cancer†

Charlotte Proudhon, F. Bidard, J. Pierga, 2016, Molecular oncology.

Prognostic value of peripheral blood double detection of CK19 and MUC1 mRNA positive cells detected by RT‐quantitative PCR in 94 breast cancer patients with a follow up of 9 years

F. Bidard, J. Pierga, P. de Cremoux, 2007, Molecular oncology.

Circulating tumor cells (CTC) and pathological complete response (pCR) as independent prognostic factors in inflammatory breast cancer (IBC) in a pooled analysis of two multicentre phase II trials (BEVERLY 1 & 2) of neoadjuvant chemotherapy combined with bevacizumab.

F. André, J. Lemonnier, J. Bonneterre, 2015 .

Abstract P2-02-17: T-DM1 in HER2-negative metastatic breast cancer patients with HER2-amplified circulating tumor cells: Current status of the CirCe T-DM1 phase II trial

M. Espié, M. Bollet, G. Romieu, 2016 .

Abstract P2-01-01: Establishment and validation of circulating tumor cell-based prognostic nomograms in 497 first-line metastatic breast cancer patients

B. Egleston, F. Bidard, J. Pierga, 2012 .

Clinical validity of circulating tumor cell (CTC) enumeration in 841 subjects with metastatic breast cancer (MBC).

D. Hayes, J. Pierga, S. Nakamura, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A three dimensional thermoplastic microfluidic chip for robust cell capture and high resolution imaging.

F. Bidard, J. Pierga, I. Draškovič, 2014, Biomicrofluidics.

Contemporary issues and the potential uses of capecitabine in metastatic breast cancer.

F. Bidard, J. Pierga, P. Barrett-Lee, 2009, Cancer treatment reviews.

Interaction between Herceptin® and Taxanes

J. Pierga, V. Diéras, P. Beuzeboc, 2001, Oncology.

Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial.

I. Bièche, F. Clatot, J. Lemonnier, 2020 .

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Helping patients communicate with oncologists when cancer treatment resistance occurs: a sequential collaborative mixed-method study (HECTOR) to develop, test and implement a patient communication aid. (Preprint)

J. Pierga, S. Piperno-Neumann, P. Cottu, 2020, JMIR Research Protocols.

Phase II study of sequential docetaxel (Taxotere®, TXT) and doxorubicin (Dox) as primary chemotherapy (CT) for large operable breast cancer (BC)

J. Pierga, V. Girre, V. Diéras, 1999 .

ESR1 Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer

F. Bidard, J. Pierga, L. Cabel, 2019, Journal of Breast Cancer.

[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].

M. Espié, X. Pivot, J. Pierga, 2012, Bulletin du cancer.

Trastuzumab in HER2-negative early breast cancer as adjuvant treatment for circulating tumor cells (CTCs) (Treat CTC).

C. Sotiriou, D. Mavroudis, S. Litière, 2014 .

A single droplet digital PCR for ESR1 activating mutations detection in plasma

A. Vincent-Salomon, I. Bièche, M. Stern, 2019, bioRxiv.

First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.

B. Asselain, F. Bidard, J. Pierga, 2017, Anticancer research.

Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

J. Pierga, I. Smith, C. Thomssen, 2011, Breast Cancer Research and Treatment.

An open-label randomized, multicenter, phase II study on neoadjuvant treatment with trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus bevacizumab according to positron emission tomography (PET) value modification in patients with early stage HER2-positive breast cancer (AVATAXHER): D

J. Darcourt, T. Petit, J. Pierga, 2012 .

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.

A. Tan, J. Pierga, C. Jackisch, 2020, The Lancet. Oncology.

552 Evaluation of the pharmacokinetic (PK) interactions between cetuximab and irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing advanced solid tumors. Results of a phase I study

E. Raymond, J. Pierga, S. Faivre, 2003 .

Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial

A. Vincent-Salomon, I. Bièche, F. Bidard, 2018, Clinical Cancer Research.

5017 Multinational study (n = 2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): updated results of MO19391

P. Kellokumpu-Lehtinen, J. Pierga, I. Smith, 2009 .

Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study.

J. Pierga, V. Girre, V. Diéras, 2013, European journal of cancer.

Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method.

M. Espié, M. Marty, J. Pierga, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract PD6-6: A pooled analysis of the prognostic relevance of circulating tumor cells in early breast cancer

P. Fasching, T. Fehm, A. Lucci, 2013 .

Management of Phyllodes Breast Tumors

M. Bollet, F. Reyal, J. Pierga, 2011, The breast journal.

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study

T. Petit, J. Prevost, J. Pierga, 2020, EClinicalMedicine.

Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases

A. Viale, J. Reis-Filho, L. Norton, 2017, Clinical Cancer Research.

A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.

X. Pivot, J. Pierga, I. Smith, 2014, Breast.

Dose escalation and pharmacokinetic study of capecitabine and irinotecan (CPT-11) in gastro-intestinal (GI) tumors

J. Pierga, V. Diéras, P. Canal, 2001 .

Cancer during pregnancy: Factors associated with termination of pregnancy and perinatal outcomes.

J. Pierga, F. Goldwasser, V. Tsatsaris, 2021, European journal of obstetrics, gynecology, and reproductive biology.

Treatment of Malignant Gliomas in the Elderly

K. Hoang-Xuan, P. Cornu, F. Baillet, 1999, Journal of Neuro-Oncology.

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer

F. Bidard, J. Pierga, M. Tanguy, 2018, npj Breast Cancer.

Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.

M. Espié, M. Edelman, F. Reyal, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Secondary solid malignant tumors occurring after bone marrow transplantation for severe aplastic anemia given thoraco-abdominal irradiation.

J. Pierga, J. Cosset, M. Henry-Amar, 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta.

D. Stoppa-Lyonnet, J. Pierga, G. Milano, 1996, European journal of cancer.

MO19391: An open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent (LR) or metastatic breast cancer (MBC)

N. Bogdanova, J. Pierga, I. Smith, 2008 .

Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients

Cyrus Chargari, J. Pierga, V. Diéras, 2009, Journal of Neuro-Oncology.

Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.

J. Pierga, V. Diéras, P. Beuzeboc, 1997, Gynecologic oncology.

Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer.

J. Pierga, S. Gerber, C. Bourgier, 2015 .

Multimodal adjuvant treatment and liver transplantation for advanced hepatocellular carcinoma. A pilot study

D. Dhumeaux, J. Pierga, C. Duvoux, 1994, Cancer.

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy

R. Rouzier, F. Reyal, F. Bidard, 2016, PloS one.

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy

R. Rouzier, F. Reyal, F. Bidard, 2015, PloS one.

Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers

P. Møller, Å. Borg, N. Loman, 2007, Hereditary cancer in clinical practice.

Low-dose (one gray) total-lymphoid irradiation for extensive, drug-resistant chronic graft-versus-host disease.

J. Pierga, J. Cosset, H. Esperou, 1990, Transplantation.

Dysgerminoma in a pure 45,X Turner syndrome: report of a case and review of the literature.

M. Espié, M. Marty, J. Pierga, 1994, Gynecologic oncology.

Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience.

A. Vincent-Salomon, J. Pierga, V. Diéras, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Carcinoma of the choroid plexus: a pediatric experience.

J. Pierga, J. Habrand, M. Terrier-Lacombe, 1993, Medical and pediatric oncology.

Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa

F. Bidard, J. Pierga, V. Diéras, 2013, Journal of Neuro-Oncology.

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy

F. Bidard, J. Pierga, P. Cottu, 2020, Breast Cancer Research.

ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics

F. Bidard, J. Pierga, G. Bataillon, 2019, Oncogene.

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab

I. Bièche, B. Asselain, M. Marty, 2013, British Journal of Cancer.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis

S. Sleijfer, L. Esserman, B. Naume, 2018, Journal of the National Cancer Institute.

Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity.

J. Pierga, V. Diéras, A. Fourquet, 2017, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

High-Accuracy Determination of Microsatellite Instability Compatible with Liquid Biopsies.

M. Stern, F. Bidard, J. Pierga, 2020, Clinical chemistry.

Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial

M. Campone, F. Bidard, J. Pierga, 2021, British Journal of Cancer.

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial

P. Fasching, T. Fehm, C. Sotiriou, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.

T. Delozier, M. Campone, T. Petit, 2012, The Lancet. Oncology.

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

Alain Viari, Thomas Bachelot, Michael R. Stratton, 2016, Nature Communications.

Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity

A. Vincent-Salomon, O. Delattre, C. Lucchesi, 2007, Breast Cancer Research.

A prognostic DNA signature for T1T2 node‐negative breast cancer patients

Anne Vincent-Salomon, Bernard Asselain, Olivier Delattre, 2010, Genes, chromosomes & cancer.

Disseminated Tumor Cells of Breast Cancer Patients: A Strong Prognostic Factor for Distant and Local Relapse

J. Thiery, A. Vincent-Salomon, F. Bidard, 2008, Clinical Cancer Research.

A DNA methylation-based liquid biopsy for triple-negative breast cancer

M. Stern, F. Bidard, J. Pierga, 2021, npj Precision Oncology.

Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer

J. Lemonnier, F. Bidard, J. Pierga, 2021, NPJ breast cancer.

Circulating Tumor Cells for Cancer Management.

J. Pierga, 2019, Clinical chemistry.

Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR.

A. Vincent-Salomon, M. Ychou, M. Stern, 2018, Clinical chemistry.

Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?

I. Bièche, F. Bidard, J. Pierga, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.

M. Campone, G. Romieu, J. Pierga, 2013, The Lancet. Oncology.

High purity microfluidic sorting and analysis of circulating tumor cells: towards routine mutation detection.

François-Clément Bidard, Jean-Louis Viovy, Laurent Malaquin, 2015, Lab on a chip.

Translating metastasis-related biomarkers to the clinic—progress and pitfalls

J. Thiery, J. Soria, F. Bidard, 2013, Nature Reviews Clinical Oncology.

Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions

A. Vincent-Salomon, M. Stern, F. Bidard, 2016, Expert review of molecular diagnostics.

Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts

S. Vacher, S. Roman-Roman, I. Bièche, 2014, Clinical Cancer Research.

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials

T. Fehm, M. Piccart, M. Ignatiadis, 2012, Cancer and Metastasis Reviews.

Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types

I. Bièche, M. Stern, R. Lebofsky, 2015, Molecular oncology.

2012 Landes Bioscience. Do not distribute. Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients

J. Blay, J. Pierga, I. Ray-Coquard, 2012 .

Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy

F. André, M. Lacroix-Triki, B. Asselain, 2019, Proceedings of the National Academy of Sciences.

Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis.

O. Delattre, W. Cacheux, J. Pierga, 2010, Anticancer research.

Clinical Significance of Immunocytochemical Detection of Tumor Cells Using Digital Microscopy in Peripheral Blood and Bone Marrow of Breast Cancer Patients

Anne Vincent-Salomon, Patricia de Cremoux, J. Thiery, 2004, Clinical Cancer Research.

Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients?

J. Pierga, V. Girre, V. Diéras, 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

A. Tutt, M. Piccart, C. Hudis, 2017, Breast.

Non-Sentinel Lymph Node Metastasis Prediction in Breast Cancer with Metastatic Sentinel Lymph Node: Impact of Molecular Subtypes Classification

A. Vincent-Salomon, R. Rouzier, F. Reyal, 2012, PloS one.

The Molecular Subtype Classification Is a Determinant of Sentinel Node Positivity in Early Breast Carcinoma

Roman Rouzier, Anne Vincent-Salomon, Fabien Reyal, 2011, PloS one.

Time to Pregnancy, Obstetrical and Neonatal Outcomes after Breast Cancer: A Study from the Maternity Network for Young Breast Cancer Patients

F. Reyal, J. Pierga, E. Laas, 2021, Cancers.

Circulating tumor cells: clinical validity and utility

F. Bidard, J. Pierga, C. Proudhon, 2017, International Journal of Clinical Oncology.

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6.

B. Asselain, J. Pierga, R. Salmon, 1994, European journal of cancer.

UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.

J. Lemonnier, M. Campone, J. Canon, 2019, European journal of cancer.

Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study

F. Bidard, J. Pierga, F. Dalenc, 2021, Breast cancer research : BCR.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

T. Fehm, A. Rademaker, C. Caldas, 2019, Critical reviews in oncology/hematology.

Cancers du sein : chimiothérapie néo-adjuvante Déterminants de la réponse à la chimiothérapie néo-adjuvante dans les cancers du sein Predictors of response to neoadjuvant chemotherapy for breast cancer

F. Reyal, F. Bidard, J. Pierga, 2011 .

PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy

A. Vincent-Salomon, F. Reyal, J. Pierga, 2021, Cancers.

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

G. Thomas, D. Cox, H. Blanché, 2016, Breast Cancer Research.

Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients

Olivier Lantz, Fabian Birzele, Roland Schmucki, 2015, International journal of cancer.

Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies

S. Michiels, F. André, J. Lemonnier, 2019, Breast Cancer Research and Treatment.

Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age.

B. Asselain, J. Pierga, V. Girre, 2004, Breast.

Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response.

J. Pierga, V. Diéras, P. Beuzeboc, 2003, European journal of cancer.

Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first‐line doxorubicin‐containing chemotherapy

B. Asselain, J. Pierga, V. Girre, 2001, Cancer.

Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients.

B. Asselain, J. Pierga, V. Diéras, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer.

B. Asselain, J. Pierga, V. Diéras, 2000, European journal of cancer.

Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer

A. Vincent-Salomon, B. Asselain, J. Pierga, 2000, British Journal of Cancer.

Breast tumour response to primary chemotherapy predicts local and distant control as well as survival.

B. Asselain, J. Pierga, P. Beuzeboc, 1995, European journal of cancer.

Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma

A. Vincent-Salomon, R. Rouzier, M. Bollet, 2014, British Journal of Cancer.

Long-Term Prognostic Performance of Ki67 Rate in Early Stage, pT1-pT2, pN0, Invasive Breast Carcinoma

A. Vincent-Salomon, M. Bollet, F. Reyal, 2013, PloS one.

Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma

A. Vincent-Salomon, M. Bollet, F. Reyal, 2012, PloS one.

Gastric metastasis of breast cancer: a single centre retrospective study.

W. Cacheux, F. Reyal, J. Pierga, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients.

M. Espié, X. Pivot, J. Pierga, 2011, British journal of clinical pharmacology.

Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer.

J. Pierga, S. Gerber, C. Bourgier, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer

M. Stern, F. Bidard, J. Pierga, 2016, Molecular oncology.

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.

A. Schneeweiss, C. Denkert, A. Buzdar, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays

Jean Salamero, François-Clément Bidard, Jean-Louis Viovy, 2010, Proceedings of the National Academy of Sciences.

The impact of expression profiling on prognostic and predictive testing in breast cancer

J. Reis-Filho, J. Pierga, J S Reis-Filho, 2006, Journal of Clinical Pathology.

Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients

J. Blay, J. Pierga, I. Ray-Coquard, 2012, Oncoimmunology.

FISH-in-CHIPS: A Microfluidic Platform for Molecular Typing of Cancer Cells.

François-Clément Bidard, Jean-Yves Pierga, Jean-Louis Viovy, 2017, Methods in molecular biology.

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

M. Espié, M. Mathieu, M. Marty, 2010, Breast Cancer Research and Treatment.

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase.

E. Rutgers, J. Bogaerts, F. Cardoso, 2011, European journal of cancer.

MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.

E. Rutgers, F. Cardoso, G. Viale, 2020 .

Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art

J. Pierga, F. Lerebours, L. Cabel, 2021, Cancers.

Cancers du sein : chimiothérapie néo-adjuvante Chimiothérapie néo-adjuvante des cancers du sein Neoadjuvant chemotherapy in breast cancer

F. Reyal, F. Bidard, J. Pierga, 2011 .

Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.

M. Piccart, E. Rutgers, S. Litière, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions.

M. Stern, F. Bidard, J. Pierga, 2018, Journal of visualized experiments : JoVE.

Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

A. Glas, R. Bernards, C. Sotiriou, 2016 .

Title : 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

A. Glas, R. Bernards, C. Sotiriou, 2022 .

Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery

R. Rouzier, F. Reyal, J. Pierga, 2016, PloS one.

Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data

J. Bonneterre, M. Campone, T. Petit, 2014, Clinical Cancer Research.

Circulating tumor cells in breast cancer 5

F. Bidard, J. Pierga, C. Proudhon, 2016 .

Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells.

J. Thiery, A. Vincent-Salomon, F. Bidard, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90).

B. Asselain, J. Pierga, P. Beuzeboc, 1998, British Journal of Cancer.

Establishment and Validation of Circulating Tumor Cell–Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients

G. Hortobagyi, A. Giordano, B. Egleston, 2013, Clinical Cancer Research.

Primary analysis of study MO19391, an open-label safety study of bevacizumab (B) plus taxane-based therapy as 1st-line treatment of patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC).

J. Pierga, I. Smith, C. Thomssen, 2009 .

An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.

J. Bogaerts, J. Bartlett, K. Zaman, 2013, European journal of cancer.

[Management of malignant phyllodes tumors of the breast: the experience of the Institut Curie].

M. Bollet, F. Reyal, J. Pierga, 2009, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

ESR1 mutations: a new biomarker in breast cancer

F. Bidard, J. Pierga, E. Jeannot, 2019, Expert review of molecular diagnostics.

Abstract S6-06: High-depth massively parallel sequencing reveals heterogeneity between primary tumor and metastatic deposits in de novo metastatic breast cancer patients prior to exposure to systemic therapy

J. Reis-Filho, L. Norton, B. Weigelt, 2013 .

Early drop of circulating tumor cells (CTC) and increase of circulating endothelial cells (CEC) during neoadjuvant chemotherapy (CT) combined with bevacizumab in HER2-negative inflammatory breast cancer (IBC) in multicenter phase II trial BEVERLY 1.

T. Delozier, F. André, J. Bonneterre, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours

J. Pierga, V. Diéras, R. Guimbaud, 2005, British Journal of Cancer.

Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.

J. Pierga, Y. Bécouarn, J. Raoul, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.

J. Pierga, P. Beuzeboc, P. Pouillart, 1997, British Journal of Cancer.

Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis.

M. Beckmann, P. Fasching, M. Fernö, 2021, European journal of cancer.

Disseminated Tumor Cells Predict Efficacy of Regional Nodal Irradiation in Early Stage Breast Cancer.

A. Vincent-Salomon, F. Bidard, J. Pierga, 2019, International journal of radiation oncology, biology, physics.

Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer.

A. Vincent-Salomon, Y. Rycke, F. Bidard, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study.

C. Tournigand, J. Coste, J. Pierga, 2014, The journal of pain : official journal of the American Pain Society.

Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer

P. Opolon, L. Zitvogel, G. Kroemer, 2019, Oncoimmunology.

Survival of breast cancer patients with meningeal carcinomatosis.

F. Bidard, J. Pierga, V. Girre, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Meningeal carcinomatosis in HER2-overexpressing breast cancers

F. Bidard, J. Pierga, V. Diéras, 2009, Journal of Neuro-Oncology.

[Disseminated and circulating tumor cells in gastrointestinal oncology].

F. Bidard, J. Pierga, P. Mariani, 2012, Bulletin du cancer.

Disseminated and circulating tumor cells in gastrointestinal oncology.

M. Ducreux, F. Bidard, J. Pierga, 2012, Critical reviews in oncology/hematology.

Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

A. Vincent-Salomon, F. Reyal, J. Pierga, 2019, Clinical Cancer Research.

[A peripheral primary neuroectodermal tumour of the lung in a man of 49 years].

J. Pierga, V. Laurence, C. Daniel, 2013, Revue des maladies respiratoires.

International study on inter-reader variability for circulating tumor cells in breast cancer

S. Sleijfer, T. Fehm, E. Perez, 2014, Breast Cancer Research.

Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens

T. Petit, J. Pierga, M. Mouret-Reynier, 2018, Breast Cancer Research and Treatment.

Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer

F. Bertucci, J. Pierga, P. Viens, 2019, Journal of clinical medicine.

Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis

F. Reyal, J. Pierga, E. Laas, 2020, PloS one.

Favourable outcome after plasmapheresis for vincristine overdose

J. Pierga, P. Beuzeboc, P. Pouillart, 1992, The Lancet.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

M. Espié, D. Khayat, G. Romieu, 2013, The Lancet. Oncology.

Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial

M. Espié, F. Bidard, J. Pierga, 2019, General Session Abstracts.

Abstract GS5-07: International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer: Results from the PADDY study

M. Fernö, R. Aft, D. Wallwiener, 2019, General Session Abstracts.

Breast Cancer Associated With Idiopathic Thrombocytopenic Purpura: A Single Center Series of 10 Cases

J. Pierga, V. Diéras, P. Pouillart, 2004, American journal of clinical oncology.

Correction: Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma

A. Vincent-Salomon, M. Bollet, F. Reyal, 2012, PLoS ONE.

Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?

M. Bollet, F. Reyal, J. Pierga, 2011, International journal of radiation oncology, biology, physics.

[Early stage breast cancer: is exclusive radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?].

M. Bollet, F. Reyal, J. Pierga, 2009, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Liver metastases from breast cancer: Surgical resection or not? A case-matched control study in highly selected patients.

V. Servois, F. Reyal, J. Pierga, 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort

Roman Rouzier, Fabien Reyal, Marick Lae, 2015, British Journal of Cancer.

HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens

F. Reyal, J. Pierga, E. Laas, 2021, Cancers.

HER2 gene status assessment in micrometastatic cells in bone marrow (BM) of breast cancer patients by fluorescence in situ hybridization (FISH)

J. Thiery, A. Vincent-Salomon, J. Pierga, 2004 .

Impact of time to local recurrence on the occurrence of metastasis in breast cancer patients treated with neoadjuvant chemotherapy: A random forest survival approach

R. Rouzier, F. Reyal, J. Pierga, 2019, PloS one.

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort

R. Rouzier, F. Reyal, J. Pierga, 2015, British journal of cancer.

Randomized trial comparing two different modalities of administration of the same cytotoxic drugs in metastatic breast cancer.

B. Asselain, J. Pierga, V. Diéras, 1995, The Journal of infusional chemotherapy.

Long-Term Prognostic Performance of Ki 67 Rate in Early Stage , pT 1pT 2 , pN 0 , Invasive Breast Carcinoma

A. Vincent-Salomon, M. Bollet, F. Reyal, 2013 .

[An unusual adrenal tumor: Ewing tumor].

O. Delattre, J. Pierga, F. Tissier, 2011, Annales de pathologie.

Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study

M. Campone, F. Bidard, J. Pierga, 2012, Breast Cancer Research.

Long-Term Follow Up of High-Dose Chemotherapy With Autologous Stem Cell Rescue in Adults With Ewing Tumor

J. Pierga, P. Pouillart, G. de Pinieux, 2005, American journal of clinical oncology.

Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance

Anne Vincent-Salomon, Valérie Choesmel, J. Thiery, 2004, Breast Cancer Research.

Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.

M. Espié, D. Khayat, G. Romieu, 2015, European journal of cancer.

Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma

A. Vincent-Salomon, S. Vacher, A. Lièvre, 2018, Clinical Cancer Research.

Human Papillomavirus Mutational Insertion: Specific Marker of Circulating Tumor DNA in Cervical Cancer Patients

Olivier Lantz, Jérôme Couturier, P. Petrow, 2012, PloS one.

Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy

F. Reyal, J. Pierga, E. Laas, 2019, PloS one.

Second malignancies after breast cancer: the impact of different treatment modalities

B. Asselain, J. Pierga, L. Gambotti, 2008, British Journal of Cancer.

Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin, and 5-fluorouracil: a phase II study.

J. Pierga, V. Diéras, P. Beuzeboc, 1996, Gynecologic oncology.

Breast Cancer (BC) Is a Window of Opportunity for Smoking Cessation: Results of a Retrospective Analysis of 1234 BC Survivors in Follow-Up Consultation

F. Reyal, J. Pierga, E. Laas, 2021, Cancers.

Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer

Leon W. M. M. Terstappen, Gerhardt Attard, C. Punt, 2013, PloS one.

GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients

G. Thomas, D. Cox, H. Blanché, 2016, Oncotarget.

Abstract OT1-1-10: CirCe T-DM1 phase II trial: Assessing the relevance of HER2-amplified circulating tumor cells as a tool to select HER2-negative metastatic breast cancer for treatment with T-DM1

Y. Rycke, B. Asselain, R. Lebofsky, 2013 .

Abstract OT3-4-06: Circulating tumor cells to guide the choice between chemotherapy and hormone therapy as first line treatment for hormone receptors positive metastatic breast cancer patients: the STIC CTC METABREAST trial

B. Asselain, F. Bidard, J. Pierga, 2012 .

J. Lemonnier, G. Romieu, J. Pierga, 2020, Pharmaceuticals.

260P Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial

J. Pierga, X. Durando, V. Diéras, 2022, Annals of Oncology.

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.

Thomas Bachelot, Thierry Petit, Pierre Kerbrat, 2014, The Lancet. Oncology.

Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models

R. Rouzier, F. Reyal, V. Gardeux, 2015, British Journal of Cancer.

[Management of inflammatory breast cancer after neo-adjuvant chemotherapy].

M. Bollet, F. Reyal, J. Pierga, 2011, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Management of inflammatory breast cancer after neoadjuvant chemotherapy.

M. Bollet, F. Reyal, J. Pierga, 2011, International journal of radiation oncology, biology, physics.

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

M. Espié, G. Romieu, I. Pauporté, 2018, Breast.

CirculatingTumor Cell Detection Predicts Early Metastatic RelapseAfter Neoadjuvant Chemotherapy in Large Operable and LocallyAdvanced Breast Cancer in a Phase II RandomizedTrial

J. Pierga, S. Delaloge, E. Brain, 2008 .

Neoadjuvant chemotherapy in young breast cancer patients: correlation between response and relapse?

B. Asselain, J. Pierga, V. Diéras, 1999, European journal of cancer.

Is primary chemotherapy useful for all patients with primary invasive breast cancer?

A. Harris, B. Asselain, J. Pierga, 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore

F. Reyal, J. Pierga, E. Laas, 2021, British Journal of Cancer.

Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program

L. Zelek, M. Namer, J. Pierga, 2004, Breast Cancer Research and Treatment.

Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer

A. Vincent-Salomon, R. Rouzier, F. Reyal, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Locoregional treatment for breast carcinoma after Hodgkin's lymphoma: the breast conservation option.

M. Bollet, F. Reyal, J. Pierga, 2010, International journal of radiation oncology, biology, physics.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Dual time point [18F]FLT-PET for differentiating proliferating tissues vs non-proliferating tissues

J. Lemonnier, J. Pierga, O. Couturier, 2019, EJNMMI Research.

A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial.

X. Pivot, J. Pierga, I. Smith, 2013 .

Phase I Combining a P-Glycoprotein Inhibitor, MS209, in Combination with Docetaxel in Patients with Advanced Malignancies

D. Lacombe, J. Bonneterre, J. Pierga, 2005, Clinical Cancer Research.

Phase ICombining a P-Glycoprotein Inhibitor , MS 209 , in Combinationwith Docetaxel in Patients with AdvancedMalignancies

D. Lacombe, J. Bonneterre, J. Pierga, 2005 .

Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)

J. Lemonnier, F. Bidard, J. Pierga, 2019, Angiogenesis.

Abstract P2-16-06: Final Overall Survival Results, Including Analysis of Patients with Triple-Negative Disease and Aged ≥70 Years, from the ATHENA Study Evaluating First-Line Bevacizumab-Containing Therapy for Locally Recurrent/Metastatic Breast Cancer

G. Manikhas, J. Pierga, C. Thomssen, 2010 .

Ewing's sarcoma of the rectum: can we afford not to use molecular pathology?

J. Reis-Filho, J. Pierga, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study

C. Tournigand, J. Coste, J. Pierga, 2017, PloS one.

Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy

R. Rouzier, X. Sastre, F. Reyal, 2015, British Journal of Cancer.

Emergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: An exploratory analysis of the PADA-1 trial

I. Bièche, F. Clatot, J. Lemonnier, 2019, Annals of Oncology.

Prospective and Comparative Evaluation of the Toxicity of Adjuvant Concurrent Chemoradiotherapy After Neoadjuvant Chemotherapy for Breast Cancer

M. Bollet, F. Reyal, J. Pierga, 2013, American journal of clinical oncology.

Concurrent administration of trastuzumab with locoregional breast radiotherapy: long-term results of a prospective study

A. Vincent-Salomon, J. Pierga, P. Beuzeboc, 2014, Breast Cancer Research and Treatment.

The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study.

M. Bollet, J. Pierga, A. Fourquet, 2011, European journal of cancer.

[Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency].

J. Pierga, J. Couturier, P. Beuzeboc, 1996, Bulletin du cancer.

Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers

A. Vincent-Salomon, R. Rouzier, F. Reyal, 2017, PloS one.

Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.

D. Cox, H. Bonnefoi, G. Romieu, 2017, European journal of cancer.

Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma

A. Vincent-Salomon, R. Rouzier, F. Reyal, 2015, British Journal of Cancer.

Neoadjuvant Concurrent Radiotherapy and Chemotherapy in Early Breast Cancer Patients: Long-Term Results of a Prospective Phase II Trial

A. Vincent-Salomon, J. Pierga, A. Fourquet, 2021, Cancers.

Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population

R. Rouzier, F. Reyal, B. Asselain, 2015, PloS one.

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.

J. Lemonnier, J. Pierga, P. Viens, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose-intensified chemotherapy and additional Docetaxel may improve inflammatory breast cancer patients outcome over two decades: Results from Institut Curie protocols 1977–1987 and two consecutive French multicenter trials Pegase 02 (1995–96) and Pegase 05 (1997–99)

B. Asselain, J. Pierga, P. Viens, 2004 .

Dose-intensified chemotherapy and additional Docetaxel may improve inflammatory breast cancer patients outcome over two decades: Results from Institut Curie protocols 1977-1987 and two consecutive French multicenter trials Pegase 02 (1995-96) and Pegase 05 (1997-99).

B. Asselain, J. Pierga, P. Viens, 2004, Journal of Clinical Oncology.

Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution

J. Pierga, E. Fourme, C. Dubot, 2017, Supportive Care in Cancer.

Follow-up thallium-201 scintigraphy after mantle field radiotherapy for Hodgkin's disease.

C. Maunoury, J. Pierga, J. Cosset, 1993, International journal of radiation oncology, biology, physics.

Circulating tumor cell count and thrombosis in metastatic breast cancer

F. Bidard, J. Pierga, V. Diéras, 2017, Journal of thrombosis and haemostasis : JTH.

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer

F. Bidard, J. Pierga, M. Tanguy, 2018, npj Breast Cancer.

A Question Prompt List for advanced cancer patients promoting advance care planning: a French randomised trial.

J. Pierga, P. Cottu, L. Copel, 2020, Journal of pain and symptom management.

A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer

C. Sotiriou, C. Desmedt, C. Denkert, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[Monocentric evaluation of the skin and cardiac toxicities of the concomitant administration of trastuzumab and radiotherapy].

M. Bollet, J. Pierga, A. Fourquet, 2009, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

ASSOCIATION BETWEEN TUMOR EGFR AND KRAS MUTATION STATUS AND CLINICAL OUTCOMES IN NSCLC PATIENTS RANDOMIZED TO SORAFENIB PLUS BEST SUPPORTIVE CARE ( BSC ) OR BSC ALONE : SUBANALYSIS OF THE PHASE III MISSION TRIAL

M. Espié, M. Dowsett, R. Gelber, 2012 .

Pathologic Response to Short Intensified Taxane-free Neoadjuvant Chemotherapy in Patients with Highly Proliferative Operable Breast Cancer

A. Vincent-Salomon, J. Pierga, V. Diéras, 2012, American journal of clinical oncology.

A Multicenter Randomized Phase II Study of Sequential Epirubicin/Cyclophosphamide Followed by Docetaxel with or without Celecoxib or Trastuzumab According to HER2 Status, as Primary Chemotherapy for Localized Invasive Breast Cancer Patient.

M. Mathieu, M. Marty, J. Pierga, 2009 .

Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients

S. Vacher, I. Bièche, F. Bidard, 2019, Cancers.

Anal canal cancer treatment: practical limitations of routine prescription of concurrent chemotherapy and radiotherapy

J. Pierga, L. Chauveinc, V. Mosseri, 2003, British Journal of Cancer.

Circulating tumor DNA detection in hepatocellular carcinoma.

F. Bidard, J. Pierga, B. Buecher, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial.

M. Espié, D. Khayat, G. Romieu, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort

G. Thomas, D. Cox, H. Blanché, 2017, npj Breast Cancer.

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy

F. Bidard, J. Pierga, P. Cottu, 2020, Breast cancer research : BCR.

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

M. Espié, M. Bollet, F. Bidard, 2019, Breast Cancer Research.

Abstract S3-01: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy

S. Sleijfer, B. Naume, A. Lucci, 2017 .

Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial

W. Cacheux, M. Ychou, M. Stern, 2016 .

Abstract P2-02-08: Initial circulating tumor cell count and venous thrombosis-free interval in the course of metastatic breast cancer

F. Bidard, J. Pierga, V. Diéras, 2016 .

Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy

F. Reyal, J. Pierga, P. Santulli, 2021, Frontiers in Oncology.

Tolerability and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) in elderly patients with advanced breast cancer (aBC): Subpopulation analysis of the MO19391 study.

J. Pierga, C. Thomssen, K. Pritchard, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thallium-201 scintigraphy is not predictive of late cardiac complications in patients with Hodgkin's disease treated with mediastinal radiation.

J. Pierga, A. Rey, J. Cosset, 2000, International journal of radiation oncology, biology, physics.

Rate of Distant Metastases on 18F-FDG PET/CT at Initial Staging of Breast Cancer: Comparison of Women Younger and Older Than 40 Years

J. Pierga, V. Diéras, V. Lebon, 2017, The Journal of Nuclear Medicine.

Transcriptomic Profiles and Circulating Tumor Cell Detection in Primary Breast Cancer.

M. Espié, F. André, F. Reyal, 2009 .

[Cerebral metastases: radiotherapy and chemotherapy].

J. Pierga, S. Helfré, 1999, Neuro-Chirurgie.

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival

F. Bidard, J. Pierga, O. Trédan, 2017, British Journal of Cancer.

Abstract 4599: Detecting MSI phenotype in circulating blood DNA

I. Bièche, M. Stern, F. Bidard, 2018, Clinical research.

Prognostic impact of residual HPV ctDNA detection after chemoradiotherapy for anal canal carcinoma.

S. Vacher, A. Lièvre, W. Cacheux, 2018 .

Clinical utility of circulating tumor cells in metastatic breast cancer.

F. Bidard, J. Pierga, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract P2-01-04: Long term independent prognostic impact of circulating tumor cells detected before neoadjuvant chemotherapy in non-metastatic breast cancer: 70 months analysis of the REMAGUS02 study

A. Vincent-Salomon, M. Marty, F. Bidard, 2012 .

Clinical utility of circulating tumor cells: an update

F. Bidard, J. Pierga, A. Vasseur, 2020 .

P1-06-12: Circulating Tumor Cells (CTC) Monitoring during Phase II Study with Lapatinib (L) and Capecitabine (C) in Patients with Brain Metastases from HER2−Positive (+) Metastatic Breast Cancer (MBC) before Whole Brain Radiotherapy (WBR): LANDSCAPE Study.

M. Campone, G. Romieu, F. Bidard, 2011 .

Abstract PD2-06: CirculatingESR1mutation detection rate and early decrease under first line aromatase inhibitor and palbociclib in the PADA-1 trial (UCBG-GINECO)

I. Bièche, J. Lemonnier, F. Bidard, 2019, Poster Discussion Abstracts.

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

A. Tutt, M. Piccart, C. Hudis, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

A. Tutt, M. Piccart, C. Hudis, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients

S. Vacher, I. Bièche, F. Bidard, 2019, Cancers.

Clinical utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial

C. Desmedt, M. Delorenzi, M. Piccart, 2020 .

333PCIRCULATING TUMOR CELL COUNT AT BASELINE IS AN INDEPENDENT PROGNOSTIC FACTOR FROM PATHOLOGICAL COMPLETE RESPONSE AMONG PATIENTS TREATED FOR PRIMARY INFLAMMATORY HER2-POSITIVE BREAST CANCER: SURVIVAL RESULTS OF THE BEVERLY-2 STUDY.

J. Bonneterre, M. Campone, T. Petit, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract OT3-4-05: Use of early CIRculating tumor CElls count changes to guide the use of chemotherapy in advanced metastatic breast cancer patients: the CirCe01 randomized trial

B. Asselain, M. Campone, F. Bidard, 2012 .

Adjuvant chemotherapy and radiotherapy in liver transplantation for primary hepatocellular carcinoma: a feasibility study

D. Mathieu, D. Dhumeaux, J. Pierga, 1994 .

Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer.

A. Vincent-Salomon, J. Pierga, V. Diéras, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating tumor cells in breast cancer†

F. Bidard, J. Pierga, C. Proudhon, 2016, Molecular Oncology.

Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer

F. Bertucci, J. Pierga, P. Viens, 2019, Journal of clinical medicine.

Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data

J. Bonneterre, M. Campone, T. Petit, 2014, Clinical Cancer Research.

Clinical Significance of Immunocytochemical Detection of Tumor Cells Using Digital Microscopy in Peripheral Blood and Bone Marrow of Breast Cancer Patients

J. Thiery, A. Vincent-Salomon, J. Pierga, 2004, Clinical Cancer Research.

Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy

N. Girard, M. Stern, F. Bidard, 2018, Nature Reviews Clinical Oncology.

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: The ancillary study Circe 07 of the LAP 07 trial.

F. Bidard, J. Pierga, O. Bouché, 2013 .

Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with 5FU plus irinotecan plus leucovorin (FOLFIRI) or capecitabine plus irinotecan XELIRI plus bevacizumab.

B. Chauffert, T. Conroy, M. Ychou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radioparp: A phase I of olaparib with radiation therapy (RT) in patients with inflammatory, locoregionally advanced or metastatic triple-negative breast cancer (TNBC) or patient with operated TNBC with residual disease—Preliminary results.

A. Salomon, J. Pierga, C. Ezzili, 2020 .

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy

R. Rouzier, F. Reyal, F. Bidard, 2015, PLoS ONE.

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy

R. Rouzier, F. Reyal, F. Bidard, 2016, PloS one.

Abstract S5-3: PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer

M. Espié, H. Bonnefoi, D. Khayat, 2012 .

Phare Trial Results Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer

M. Espié, H. Bonnefoi, D. Khayat, 2012 .

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials

T. Fehm, M. Piccart, M. Ignatiadis, 2012, Cancer and Metastasis Reviews.

Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer.

J. Reis-Filho, L. Norton, A. Vincent-Salomon, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259].

A. Tutt, M. Piccart, C. Hudis, 2017, Breast.

P4-20-01: Multicentric Phase II PACS 09/Beverly1 Trial: First Efficacy and Safety Results of Neoadjuvant Chemotherapy Combined with Bevacizumab in HER2−Negative Patients with Non-Metastatic Inflammatory Breast Cancer.

T. Delozier, F. André, J. Lemonnier, 2011 .

[Radiotherapy of glioblastoma].

J. Pierga, R. de Crevoisier, R. Dendale, 1997, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[Circulating tumor cells: liquid biopsy].

J. Pierga, C. Alix-Panabières, 2014, Bulletin du cancer.